Literature DB >> 29155748

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles.

Ann L B Seynhaeve1, Timo L M Ten Hagen2.   

Abstract

Conventional imaging techniques can provide detailed information about cellular processes. However, this information is based on static images in an otherwise dynamic system, and successive phases are easily overlooked or misinterpreted. Live-cell imaging and time-lapse microscopy, in which living cells can be followed for hours or even days in a more or less continuous fashion, are therefore very informative. The protocol described here allows for the investigation of the fate of chemotherapeutic nanoparticles after the delivery of doxorubicin (dox) in living cells. Dox is an intercalating agent that must be released from its nanocarrier to become biologically active. In spite of its clinical registration for more than two decades, its uptake, breakdown, and drug release are still not fully understood. This article explores the hypothesis that lipid-based nanoparticles are taken up by the tumor cells and are slowly degraded. Released dox is then translocated to the nucleus. To prevent fixation artifacts, live-cell imaging and time-lapse microscopy, described in this experimental procedure, can be applied.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29155748      PMCID: PMC5755268          DOI: 10.3791/55405

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  19 in total

Review 1.  Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.

Authors:  Sean T Duggan; Gillian M Keating
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma.

Authors:  P G Brouckaert; G G Leroux-Roels; Y Guisez; J Tavernier; W Fiers
Journal:  Int J Cancer       Date:  1986-11-15       Impact factor: 7.396

3.  Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro/in vivo live cell imaging.

Authors:  Ann L B Seynhaeve; Bilyana M Dicheva; Saske Hoving; Gerben A Koning; Timo L M Ten Hagen
Journal:  J Control Release       Date:  2013-09-04       Impact factor: 9.776

4.  Sample drift correction following 4D confocal time-lapse imaging.

Authors:  Adam Parslow; Albert Cardona; Robert J Bryson-Richardson
Journal:  J Vis Exp       Date:  2014-04-12       Impact factor: 1.355

5.  Short-chain glycoceramides promote intracellular mitoxantrone delivery from novel nanoliposomes into breast cancer cells.

Authors:  Lília R Cordeiro Pedrosa; Timo L M Ten Hagen; Regine Süss; Albert van Hell; Alexander M M Eggermont; Marcel Verheij; Gerben A Koning
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

6.  Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats.

Authors:  T L Ten Hagen; A H Van Der Veen; P T Nooijen; S T Van Tiel; A L Seynhaeve; A M Eggermont
Journal:  Int J Cancer       Date:  2000-09-15       Impact factor: 7.396

7.  Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies.

Authors:  Alberto A Gabizon; Olga Lyass; Gerald J Berry; Mark Wildgust
Journal:  Cancer Invest       Date:  2004       Impact factor: 2.176

8.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.

Authors:  A Gabizon; R Catane; B Uziely; B Kaufman; T Safra; R Cohen; F Martin; A Huang; Y Barenholz
Journal:  Cancer Res       Date:  1994-02-15       Impact factor: 12.701

9.  Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics.

Authors:  Peter Brouckaert; Nozomi Takahashi; Sandra T van Tiel; Jeroen Hostens; Alexander M M Eggermont; Ann L B Seynhaeve; Walter Fiers; Timo L M ten Hagen
Journal:  Int J Cancer       Date:  2004-04-10       Impact factor: 7.396

10.  Formulation and optimization of idarubicin thermosensitive liposomes provides ultrafast triggered release at mild hyperthermia and improves tumor response.

Authors:  Tao Lu; Wouter J M Lokerse; Ann L B Seynhaeve; Gerben A Koning; Timo L M Ten Hagen
Journal:  J Control Release       Date:  2015-11-03       Impact factor: 9.776

View more
  2 in total

1.  Spatiotemporal endothelial cell - pericyte association in tumors as shown by high resolution 4D intravital imaging.

Authors:  Ann L B Seynhaeve; Douwe Oostinga; Rien van Haperen; Hanna M Eilken; Susanne Adams; Ralf H Adams; Timo L M Ten Hagen
Journal:  Sci Rep       Date:  2018-06-25       Impact factor: 4.379

2.  Amphipathic Small Molecule AZT Compound Displays Potent Inhibitory Effects in Cancer Cell Proliferation.

Authors:  Pethaiah Gunasekaran; Ho Jin Han; Jung Hoon Choi; Eun Kyoung Ryu; Nam Yeong Park; Geul Bang; Yeo Kyung La; Sunghyun Park; Kyubin Hwang; Hak Nam Kim; Mi-Hyun Kim; Young Ho Jeon; Nak-Kyun Soung; Jeong Kyu Bang
Journal:  Pharmaceutics       Date:  2021-12-03       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.